Brian Park, PharmD

Drug Information Specialist https://www.cancertherapyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Xiuning Le, MD, PhD, discusses the future of tepotinib in the treatment of NSCLC. Dr Le is an author of a phase 2 study on tepotinib, a highly selective MET inhibitor.

Ready-to-Dilute Pemfexy Gains Additional NSCLC Indication

By

Brian Park, PharmD

December 21, 2022

Pemfexy (pemetrexed) plus pembrolizumab and platinum chemotherapy is now approved for the initial treatment of patients with metastatic, nonsquamous NSCLC.

Gene Therapy Approved for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

By

Brian Park, PharmD

December 20, 2022

The FDA has approved the gene therapy Adstiladrin (nadofaragene firadenovec-vncg) to treat high-risk, non-muscle-invasive bladder cancer.

General Oncology

Xeloda Labeling Updated Under FDA’s New Program for Older Oncology Drugs

By

Brian Park, PharmD

December 16, 2022

Project Renewal is an Oncology Center of Excellence initiative that aims to update the labeling information for certain older oncology drugs.

Investigational Therapy Gets Fast Track Status for Glioblastoma Multiforme

By

Brian Park, PharmD

December 16, 2022

In mouse models, WP1122 outperformed temozolomide.

Krazati Approved for KRAS^G12C-Mutated Locally Advanced or Metastatic NSCLC

By

Brian Park, PharmD

December 15, 2022

The approval was based on data from the phase 2 KRYSTAL-1 study.

Tecentriq Approved for Unresectable or Metastatic Alveolar Soft Part Sarcoma

By

Brian Park, PharmD

December 15, 2022

The approval was based on data from a phase 2 study that included 49 patients with unresectable or metastatic ASPS.

Endocrine Cancer

FDA Rejects Omburtamab for Neuroblastoma After Disappointing Panel Vote

By

Brian Park, PharmD

December 7, 2022

Omburtamab is an investigational radiolabeled monoclonal antibody designed to target tumor cells that express B7-H3.

Tecentriq Indication for Previously Untreated Advanced Bladder Cancer Withdrawn

By

Brian Park, PharmD

December 7, 2022

The decision to withdraw the indication was made based on findings from the phase 3 IMvigor130 trial.

General Medicine

FDA Pulls Authorization for Bebtelovimab Due to Nonsusceptible SARS-CoV-2 Variants

By

Brian Park, PharmD

December 5, 2022

Bebtelovimab is not expected to neutralize the SARS-CoV-2 variants BQ.1 and BQ.1.1, which are the most prevalent variants in the United States.

Epcoritamab Granted Priority Review for Relapsed/Refractory Large B-Cell Lymphoma

By

Brian Park, PharmD

November 23, 2022

Epcoritamab is designed to bind to CD3 on T cells and CD20 on B cells, inducing T-cell-mediated killing of CD20+ cells.

Next post in Lymphoma

Atezolizumab Does Not Improve PFS in Previously Untreated Follicular Lymphoma